Stock market today: S&P 500 extends monthly win streak despite Nvidia-led stumble
Investing.com - H.C. Wainwright has assumed coverage on Novavax (NASDAQ:NVAX) with a Buy rating and a $10.00 price target, according to a research note released Thursday. The target represents potential upside from the current price of $7.58, with analyst targets ranging from $6 to $25. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment.
The research firm cited Novavax’s "unique and proven technology" as the foundation for its positive outlook on the commercial-stage biotechnology company, which focuses on developing vaccines against infectious diseases. The company’s financial health supports this outlook, with a healthy gross profit margin of 57.18% and revenue growth of 9.22% over the last twelve months.
H.C. Wainwright highlighted the company’s proprietary vaccine platform based on recombinant protein nanoparticle technology and its Matrix-M adjuvant, which has demonstrated broad immune responses and safety in clinical settings since the first COVID-19 vaccine approval in 2022.
The firm noted that Matrix-M, a patented nanoparticle formulation of saponin chemicals extracted from the soapbark tree, has attracted interest from potential partners and has been separately out-licensed.
H.C. Wainwright also pointed to Novavax’s strong clinical results in malaria and influenza vaccine programs as evidence of the platform’s versatility, adding that its traditional antigen-based approach may receive more favorable regulatory treatment compared to mRNA-based vaccines.
In other recent news, Novavax Inc. reported a surprising profit in its Q2 2025 earnings, posting a net income of $107 million, or $0.62 per diluted share. This result significantly outperformed analysts’ expectations, which had forecasted a loss of $0.06 per share. The company’s revenue also exceeded projections, reaching $239 million compared to the anticipated $156.23 million. In a separate development, Novavax announced the issuance of $225 million in convertible senior notes due 2031. This transaction included approximately $175.3 million in notes exchanged for existing convertible notes due 2027, with the remaining $49.7 million issued for cash. The new notes have a conversion price set at a 27.5% premium over a recent stock price. Additionally, the U.S. Food and Drug Administration approved updated Covid-19 vaccines with restricted eligibility, primarily for individuals 65 and older or those with specific health conditions. These developments highlight Novavax’s recent financial and operational activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.